Open AccessP1121: TAKEAIM LYMPHOMA‐ AN OPEN‐LABEL, DOSE ESCALATION AND EXPANSION TRIAL OF EMAVUSERTIB (CA‐4948) IN COMBINATION WITH IBRUTINIB IN PATIENTS WITH RELAPSED OR REFRACTORY HEMATOLOGIC MALIGNANCIES
Author(s) -
Joffe E.,
Nowakowski G.,
Tun H.,
Rosenthal A.,
Lunning M.,
Ramchandren R.,
Li C.C.,
Zhou L.,
Martinez E.,
Roemeling R.,
Earhart R.,
McMahon M.,
Isufi I.,
Leslie L.
Publication year - 2022
Publication title -
hemasphere
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 11
ISSN - 2572-9241
DOI - 10.1097/01.hs9.0000847352.16311.ea
Subject(s) - ibrutinib , medicine , lymphoma , bruton's tyrosine kinase , oncology , pharmacology , cancer research , leukemia , tyrosine kinase , chronic lymphocytic leukemia , receptor